VIRI - Virios Therapeutics slides 11% postmarket on proposed stock offering
- Virios Therapeutics ( NASDAQ: VIRI ) slid ~11% postmarket on Monday after the firm announced a proposed public stock offering .
- Net proceeds will be used primarily to advance clinical development of lead development candidate IMC-1, and for working capital and general corporate purposes.
- IMC-1 is an antiviral therapy that combines famciclovir and celecoxib designed to suppress herpes virus replication.
- There can be no assurance as to whether or when the offering may be completed, or the actual size or terms.
For further details see:
Virios Therapeutics slides 11% postmarket on proposed stock offering